(HSG) is associated with pain during the four-step procedure. This prospective, double-blind, randomized, placebo-controlled study was conducted to investigate the effect of the analgesic flurbiprofen, administered prior to HSG, in 60 women. Thirty women were randomized to receive 100 mg of flurbiprofen, orally, 1 h prior to HSG and a further 30 women were randomized to receive placebo. Injection of contrast medium was more painful than the other steps in the HSG procedure in both groups; however, there was no significant between-group difference in terms of pain experienced in the individual steps of HSG. Pain scores at 5 and 30 min after the procedure were compared between the two groups. There was a significant decrease in the visual analogue scale pain score in the flurbiprofen-treated group compared with the placebo-treated group at both time points. Thus, the authors recommend flurbiprofen as a prophylactic analgesic to be administered before HSG procedures.
Introduction
Hysterosalpingography (HSG) is one of the most frequently used initial methods for investigating infertility, and is particularly useful in the diagnosis of uterine abnormalities and intrinsic tubal disease. 1, 2 Although HSG is a minor gynaecological procedure, considerable pain can occur with insertion of cervical instrumentation, during uterine instillation of contrast media, or from peritoneal irritation secondary to contrast media spillage. 3 Different methods have been considered for reducing pain during the HSG procedure, such as using a balloon catheter instead of a metal cannula and using iodinated hydro-soluble contrast media instead of oil-based media. 3, 4 Analgesic agents such as paracetamol, 5 naproxen 6 and local anaesthetics 7 have been assessed for pain relief in HSG.
Flurbiprofen is a non-steroidal antiinflammatory drug (NSAID) with potent anti-inflammatory, analgesic and antipyretic properties. 8 The present study was designed to evaluate whether the use of oral flurbiprofen reduces the pain associated with the HSG procedure.
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School of Medicine, Dicle University, (Diyarbakir, Turkey) from September to December 2009. Outpatients attending the department and who were scheduled to undergo HSG were enrolled sequentially into the study. Cases with a history of allergy to flurbiprofen and those taking analgesics, cold remedies or anti-inflammatory drugs were excluded from the study.
All of the patients gave their informed written consent to participate in the study, which was carried out in accordance with the Declaration of Helsinki. The study did not require ethics committee approval, because analgesic therapy was already being given to patients before HSG was performed at the Department of Obstetrics and Gynaecology, School of Medicine, Dicle University.
STUDY METHODS
Patients were randomized to receive either 100 mg of flurbiprofen or placebo, orally, 1 h prior to the HSG procedure. The placebo tablet was a vitamin that was chosen for being similar -although not identical -in appearance to the study drug. Each day, two HSG procedures were carried out at the clinic: one patient was included in the treatment group, and one in the placebo group. The flurbiprofen and placebo were administered by a nurse who was not familiar with the study and the HSG procedure was carried out by a physician blinded to the study treatment.
The HSG procedure was performed in the lithotomy position. A speculum was inserted into the vagina and the cervix was visualized. The vagina and the cervix were cleaned with povidone-iodine solution (Biocadin ® solution; Kansuk Drugs, Istanbul, Turkey). A Rubin cannula was inserted into the cervical canal and water-soluble nonionic contrast medium (Omnipaque 350; Nycomed Ltd, Birmingham, UK) was injected. Sequential radiographs of the uterus, fallopian tubes and peritoneal spill (if the tubes were open) were obtained.
During the procedure, pain was examined during four steps: (i) speculum insertion; (ii) tension on the cervix caused by the tenaculum; (iii) injection of the contrast medium under pressure; and (iv) removal of the instruments by asking the patients 'Do you have pain or not?' Pain was also measured at 5 and 30 min after the procedure was completed by asking the patients to record the severity of their pain after the HSG procedure using a visual analogue scale (VAS). A detailed explanation about the VAS and its application was given personally to each woman. The VAS was a 10 cm continuous line with a scale from 0 to 10 (0, no pain; 10, very severe pain). Pain scores were also compared in patients with abnormal and normal HSG findings.
Potential side-effects of the study drug were explained to the patients and, at the followup visit patients were asked to report any side-effects that they experienced.
STATISTICAL ANALYSES
Data were calculated as mean ± SD for the continuous variables. The χ 2 -test and the independent samples t-test were used to evaluate associations between the categorical and continuous variables. Twosided P-values < 0.05 were considered to be statistically significant. Statistical analysis was carried out using the SPSS ® statistical package, version 12.0 (SPSS Inc., Chicago, IL, USA) for Windows ® .
Results
Sixty women underwent HSG procedures, 30 per group, as part of an infertility investigation; the majority of women in both groups presented with primary infertility. 
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The demographic characteristics are shown in Table 1 ; there were no significant differences in the baseline characteristics between the two groups.
There were no significant differences between the groups in terms of pain at any of the four individual steps of the procedure (data not shown). Patients in both groups experienced the most pain during injection of the contrast medium. Fewer flurbiprofentreated patients (n = 11) experienced pain during this step than placebo-treated patients (n = 15), although this difference was not statistically significant (Table 1) .
Pain scores recorded at 5 and 30 min after the procedure were also compared between the two groups; the flurbiprofen-treated patients had significantly lower VAS pain scores at both time points compared with the placebo-treated patients (P < 0.001) ( Table 2) . Similar results were found with regard to pain scores in patients with an abnormal or normal HSG: pain scores at 5 and 30 min after the procedure were similar in patients whose HSG had abnormal findings ( 
Discussion
Hysterosalpingography is one of the most common procedures used to investigate female infertility. The pain related to HSG is the chief disadvantage associated with this procedure. Thus, methods to reduce pain during HSG have been investigated. In the present study, the effect of flurbiprofen as a prophylactic analgesic administered before HSG was assessed. The HSG procedure was performed in four steps, and injection of the contrast medium under pressure was found to be the most painful step in both the treatment and placebo groups. The number of patients who had pain during this step was smaller in the flurbiprofen group, although this difference was not statistically significant. The post-procedure VAS scores at 5 and 30 min were significantly lower in the flurbiprofen group compared with the control group (P < 0.001). The pain scores in patients with normal versus abnormal HSG were not statistically significantly different.
Liberty et al. 7 evaluated the efficacy of lidocaine 25 mg/prilocaine 25 mg cream (EMLA 5%) applied to the cervix before the HSG procedure and reported that the most painful step was insertion of the cervical instrumentation. The lidocaine prilocaine cream was found to be useful for pain relief before the HSG procedure. 7 The pain scores in patients with tubal occlusion and peritubal adhesions were not significantly different between the groups in their study. 7 Elson and Ridley 5 administered paracetamol as a prophylactic analgesic to patients and found that it was ineffective for pain relief, both before and after the HSG procedure; the authors recommended giving a NSAID. Peters et al. 6 found the analgesic potency of tramadol and naproxen to be comparable, with a slightly higher incidence of adverse effects with tramadol use. Cengiz et al. 9 found that the intravenous opioid analgesic remifentanil was superior to placebo for pain relief in HSG.
In contrast to the study by Liberty et al., 7 the most painful step of the HSG procedure reported in the present study was the injection of contrast media into the uterus; patients did not report much pain during the other three steps. This may be related to differences in the way that individual health care professionals perform the HSG procedure. Both tramadol 6 and remifentanil 9 have been found to be useful before HSG, but the side-effect profiles of both drugs limit their use. NSAIDs have considerable sideeffects, mostly affecting the upper gastrointestinal system 10, 11 but, in the present study, no patient in the study group reported side-effects from taking the drug.
In conclusion, flurbiprofen, when used as a prophylactic analgesic for HSG, was effective for pain relief during and after the HSG procedure. The study group showed clinically less pain, as assessed by reduced VAS scores after HSG. Indeed, a statistically significant difference was observed, in terms of pain reported after the procedure. This finding supported the useful effect of flurbiprofen in providing pain relief for HSG. Thus, the authors recommend flurbiprofen as a prophylactic analgesic to be administered before HSG procedures.
